-
1
Lupus nephritis is a major complication of systemic lupus erythematosus, affecting 30%-60% of patients and leading to significant morbidity and mortality.
-
2
Recent clinical trials show a shift towards targeted therapies, including complement inhibitors and CAR-T therapy, moving away from non-specific immunosuppression.
-
3
Despite advancements, complete renal response rates in pivotal trials plateau at 40-50%, indicating a need for improved therapeutic strategies.
-
4
Future research should focus on pharmacogenomics, steroid-free induction protocols, and real-time molecular biomarkers to enhance treatment outcomes.
-
5
The 2025 EULAR recommendations emphasize a proactive approach to managing lupus nephritis, prioritizing complete renal remission and rigorous supportive care.
